RhythmAnalytics vs Cleerly ISCHEMIA
AI Verdict
Choose RhythmAnalytics if…
Choose RhythmAnalytics if your primary need is automated, AI-powered interpretation of cardiac arrhythmias from single-lead ECG data. This tool is ideal for healthcare professionals requiring clinical decision support for arrhythmia detection across various ECG sources, including Holter monitors, event recorders, and wearable sensors, enabling timely intervention and management.
View RhythmAnalytics →Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you require a non-invasive, AI-powered analysis of CCTA scans to determine the likelihood of coronary artery ischemia at a vessel level. This tool is best suited for physicians seeking detailed insights into coronary plaque characteristics, stenosis severity, and functional assessment to guide personalized diagnosis and treatment planning for heart disease.
View Cleerly ISCHEMIA →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | RhythmAnalytics | Cleerly ISCHEMIA |
|---|---|---|
| Pricing | Contact vendor | Contact for details |
| Deployment | Cloud-based API | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIACleerly ISCHEMIA offers a direct, interactive web-based platform with comprehensive visual reports for clinicians, and integrates with existing radiology workflows like PowerScribe to streamline operations. RhythmAnalytics is primarily an API for integration into other systems, meaning its end-user usability depends heavily on the implementing partner's interface.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA provides a more comprehensive and potentially transformative assessment of coronary artery disease by quantifying plaque characteristics, assessing stenosis, and non-invasively estimating fractional flow reserve (FFR) from CCTA scans. Its clinical validation studies demonstrated high diagnostic accuracy and prognostic utility for major adverse cardiovascular events (MACE), which goes beyond the arrhythmia detection offered by RhythmAnalytics.
Pricing & Value
Cleerly ISCHEMIACleerly ISCHEMIA demonstrates clearer value realization for providers through the existence of specific Category I CPT codes (75580 for ischemia, 75577 for plaque analysis) and a published global reimbursement rate for plaque analysis. In contrast, RhythmAnalytics' pricing is 'contact vendor' with unspecified BAA details, offering less transparency on the financial model for potential clients.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA explicitly states it has a Business Associate Agreement (BAA) and utilizes secure data transfer via Cleerly Proxy (VPN or virtual appliance), directly addressing critical enterprise requirements for data security and compliance. While RhythmAnalytics is cloud-based and HIPAA compliant, its BAA status is unspecified, which could be a hurdle for enterprise adoption.
Innovation
Cleerly ISCHEMIACleerly ISCHEMIA exhibits a higher degree of innovation by non-invasively estimating FFR and providing detailed, quantitative characterization of coronary plaque (including high-risk soft plaque) from CCTA scans, offering insights traditionally requiring more invasive procedures. While AI-powered ECG interpretation is valuable, Cleerly's advanced CCTA analysis pushes the boundaries of non-invasive cardiac diagnostics further.
Support & Docs
Cleerly ISCHEMIACleerly's website explicitly features a 'Client Support' section with a contact form for existing users, indicating a dedicated and transparent channel for assistance. For RhythmAnalytics, specific support documentation or direct support channels were not readily found in the provided information or web searches, making Cleerly's offering more clearly defined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | RhythmAnalytics | Cleerly ISCHEMIA |
|---|---|---|
| Name | RhythmAnalytics | Cleerly ISCHEMIA |
| Company | Biofourmis Singapore Pte. | Cleerly |
| Description | FDA-cleared, AI-powered cloud-based software that provides automated interpretation of cardiac arrhythmias from single-lead ECG data, offering clinical decision support for healthcare professionals and integrators. | FDA-cleared AI tool that analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. |
| Key Functionality | AI-based automated interpretation of cardiac arrhythmias; Detection of over 15 types of cardiac arrhythmias; Beat-by-beat morphology computation; ECG signal processing and analysis; QRS and Ventricular Ectopic Beat detection; QRS feature extraction, interval measurement, heart rate measurement, and rhythm analysis. | AI-enabled CCTA analysis; Non-invasive fractional flow reserve (FFR) estimation; Vessel-level ischemia likelihood determination; Coronary plaque characterization; Stenosis severity assessment; 3D digital models of coronary arteries; Comprehensive interactive web-based reports. |
| Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Radiology |
Videos
Demos, reviews, and walkthroughs featuring RhythmAnalytics and Cleerly ISCHEMIA.
Frequently Asked Questions
More Comparisons
More matchups featuring RhythmAnalytics or Cleerly ISCHEMIA
Backers
Who funded each tool's parent company.